Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 561-567

  Lahmer, Tobias ^a   Hermans, Rob ^c   Schmaderer, Christoph ^a   Chang, Jianxing ^a   Stock, Konrad ^a   Lutz, Jens ^b   Heemann, Uwe ^a   Baumann, Marcus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Aldosterone; Chronic allograft injury; Fadrozole; Spironolactone

Indexed keywords

ALDOSTERONE; CREATININE; FADROZOLE; POTASSIUM; SODIUM; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CHRONIC ALLOGRAFT INJURY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; HEART WEIGHT; HORMONE SYNTHESIS; INTERSTITIAL NEPHRITIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RAT; SODIUM BLOOD LEVEL;

ALDOSTERONE; ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR FLUID; FIBROSIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864826579     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000339649     Document Type: Article

References (26)

1. Chapman JR, O'Connell PJ, Nankivell BJ: Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
2. Campbell PM, Cascalho M, Collins AB, et al: Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
3. Cosio FG, Pelletier RP, Sedmak DD, Falkenhain ME, Henry ML, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM: Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications. Transplantation 1999; 67: 690-696.
4. Lutz J, Risch K, Liu S, Antus B, Schmaderer C, Roos M, Ouyang N, Lehmann M, Heemann U: Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006; 70: 1080-1088.
5. Macdonald JE, Kennedy N, Struthers AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-770.
6. Cohn JN, Colucci W: Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97: 4FY12F.
7. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104: 467-472.
8. Del Vecchio L, Procaccio M, Vigano S, Cusi D: Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007; 3: 42-49.
9. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
10. Caprio M, Newfell BG, la SA, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102: 1359-1367.
11. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314.
12. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y: Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol 2006; 107: 260-266.
13. Minnaard-Huiban M, Emmen JMA, Roumen L, Beugels IPE, et al: Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: Discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology 2008; 149: 28-31.
14. Stein RC, Dowsett M, Davenport J, Hedley A, Ford HT, Gazet JC, Coombes RC: Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS16949A. Cancer Res 1990; 50: 1381-1384.
15. Menard J, Gonzalez MF, Guyene TT, Bissery: A Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24: 1147-1155.
16. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC: Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens 2007; 16: 134-142.
17. Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459-1462.
18. Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA: Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007; 293:F78-F86.
19. Bedi DS, Riella LV, Tullius SG, Chandraker A: Animal models of chronic allograft injury: Contributions and limitations to understanding the mechanism of long-term graft dysfunction. Transplantation 2010; 90: 935-944.
20. Tullius SG, Reutzel-Selke A, Egermann F, et al: Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. J Am Soc Nephrol 2000; 11: 1317-1324.
21. Herrero-Fresneda I, Torras J, Cruzado JM, et al: Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127-137.
22. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ: Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944.
23. Connell JMC, Davies E: The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
24. Hermans JJ, Fischer MA, Schiffers PM, Struijker-Boudier HA: High dietary potassium chloride intake augments rat renal mineralocorticoid receptor selectivity via 11 - hydroxysteroid dehydrogenase. Biochim Biophys Acta 1999; 1472: 537-549.
25. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004; 110: 1819-1825.
26. LaSala D, Shibanaka Y, Jeng AY: Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal Biochem 2009; 394: 56-61.